Circassia Pharmaceuticals Plc Directorate Change (1204S)
December 16 2016 - 9:44AM
UK Regulatory
TIDMCIR
RNS Number : 1204S
Circassia Pharmaceuticals Plc
16 December 2016
Circassia Pharmaceuticals plc
Non-Executive Director Retirement
Oxford, UK - 16 December 2016: Circassia Pharmaceuticals plc
("Circassia" or "the Company"; LSE: CIR), a specialty
biopharmaceutical company focused on allergy and asthma, today
announces the retirement of Cathrin Petty from its Board, following
nearly seven years as a Non-Executive Director.
Dr Francesco Granata, Circassia's Chairman, commented: "On
behalf of the Board, I would like to thank Cathrin for her
significant contribution to the Company over many years, and we
wish her well in her new role as Head of European Healthcare at CVC
Capital Partners."
Commenting on her retirement, Cathrin Petty said: "I firmly
believe that Circassia is well positioned to achieve its ambition
to become a self-sustaining, world-class specialty
biopharmaceutical company. Unfortunately, the time commitments of
my new role preclude me from contributing further as a Director,
but I will continue to follow Circassia's progress keenly."
-Ends-
For further information, please contact:
Circassia Tel: +44 (0)1865 405 560
Steve Harris, Chief Executive
Officer
Julien Cotta, Chief Financial
Officer
Rob Budge, Corporate Communications
FTI Consulting Tel: +44 (0) 20 3727 1000
Ben Atwell / Simon Conway
/ Mo Noonan
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAGGGPCPUPQGCQ
(END) Dow Jones Newswires
December 16, 2016 09:44 ET (14:44 GMT)
Circassia (LSE:CIR)
Historical Stock Chart
From Apr 2024 to May 2024
Circassia (LSE:CIR)
Historical Stock Chart
From May 2023 to May 2024